{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T19:24:14Z","timestamp":1770146654198,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Drug survival measures the rate and duration of adherence to a given therapeutic agent and evaluates its long\u2010term effectiveness, safety, and real\u2010world utility. The SUSTAIN study sought to establish the drug survival and effectiveness of secukinumab for patients with severe chronic plaque psoriasis (CPP) in the Australian clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data of all patients (aged \u226518\u2009years) from Australasian Psoriasis Registry (APR) treated with secukinumab were analysed. The primary objective was to describe the drug survival of secukinumab at 9\u00a0months. Key secondary objectives included drug survival of secukinumab at 3, 6, 15, and 21\u2009months, stratified by biologic\u2010na\u00efve vs biologic\u2010experienced patients; proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75\/90\/100 responses; and changes in health\u2010related quality of life over time utilising the Dermatology Life Quality Index (DLQI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 294 patients included in this analysis, 110 (37.4%) were biologic\u2010na\u00efve and 184 (62.6%) biologic\u2010experienced. Kaplan\u2013Me\u0457er drug survival rates in biologic\u2010na\u00efve vs biologic\u2010experienced patients were 0.92 vs. 0.86 (9\u00a0months) and 0.82 vs. 0.68 (21\u2009months), respectively. The proportion of patients with PASI 75\/90\/100 responses for biologic\u2010na\u00efve vs. biologic\u2010experienced was 100\/87.7\/38.4 vs 98.5\/61.5\/27.2 (9\u00a0months) and 100\/81.0\/41.7 vs. 98.4\/62.0\/24.2 (21\u2009months), respectively. The mean (standard deviation [SD]) DLQI in biologic\u2010na\u00efve vs. experienced patients was 2.2 (4.1) vs. 3.1 (5.2) (9\u00a0months) and 1.4 (2.5) vs. 3.1 (5.3) (21\u2009months). No new safety signals were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Secukinumab demonstrated high drug survival and sustained effectiveness in Australian real\u2010world setting, in biologic\u2010na\u00efve and biologic\u2010experienced patients with severe CPP.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajd.13895","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T14:13:40Z","timestamp":1657376020000},"page":"303-311","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21\u2010month analysis in Australian routine clinical practice (<scp>SUSTAIN<\/scp> study)"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5891-5607","authenticated-orcid":false,"given":"Peter","family":"Foley","sequence":"first","affiliation":[{"name":"Skin Health Institute  Carlton Victoria Australia"},{"name":"The University of Melbourne, St Vincent's Hospital Melbourne  Fitzroy Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4043-1281","authenticated-orcid":false,"given":"Nick","family":"Manuelpillai","sequence":"additional","affiliation":[{"name":"Skin Health Institute  Carlton Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Con","family":"Dolianitis","sequence":"additional","affiliation":[{"name":"The University of Melbourne, St Vincent's Hospital Melbourne  Fitzroy Victoria Australia"},{"name":"Royal Melbourne Hospital  Parkville Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D.","family":"Cains","sequence":"additional","affiliation":[{"name":"Liverpool Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mate","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, Australia Pty Limited  Macquarie Park New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Tronnberg","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, Australia Pty Limited  Macquarie Park New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Baker","sequence":"additional","affiliation":[{"name":"Skin Health Institute  Carlton Victoria Australia"},{"name":"The University of Melbourne, St Vincent's Hospital Melbourne  Fitzroy Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.009092"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14819"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2009.08066"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S200147"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)61909\u20107"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16180"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13087"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13611"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_2_10_12_1","unstructured":"Australian product information [Cosentyx]. Vol. 2021."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895\u2010019\u20100087\u20103"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18981"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010021\u201000606\u20109"},{"key":"e_1_2_10_16_1","unstructured":"Autralasian psoriasis registry. Vol. 2021."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.11.036"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102019\u2010eular.8034"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.815"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20102900"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.13895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.13895","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.13895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T14:34:32Z","timestamp":1692628472000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.13895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/ajd.13895"],"URL":"https:\/\/doi.org\/10.1111\/ajd.13895","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"2022-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}